Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Alexander Schmitz » Publikationer » miR-155 as a Biomarker in B-Cell Malignancies

Om AU

Alexander Schmitz

miR-155 as a Biomarker in B-Cell Malignancies

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

miR-155 as a Biomarker in B-Cell Malignancies. / Due, Hanne; Svendsen, Pernille; Bødker, Julie Støve et al.
I: BioMed Research International, Bind 2016, 2016, s. 9513037.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Due, H, Svendsen, P, Bødker, JS, Schmitz, A, Bøgsted, M, Johnsen, HE, El-Galaly, TC, Roug, AS & Dybkær, K 2016, 'miR-155 as a Biomarker in B-Cell Malignancies', BioMed Research International, bind 2016, s. 9513037. https://doi.org/10.1155/2016/9513037

APA

Due, H., Svendsen, P., Bødker, J. S., Schmitz, A., Bøgsted, M., Johnsen, H. E., El-Galaly, T. C., Roug, A. S., & Dybkær, K. (2016). miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International, 2016, 9513037. https://doi.org/10.1155/2016/9513037

CBE

Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS, Dybkær K. 2016. miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International. 2016:9513037. https://doi.org/10.1155/2016/9513037

MLA

Due, Hanne et al. "miR-155 as a Biomarker in B-Cell Malignancies". BioMed Research International. 2016, 2016. 9513037. https://doi.org/10.1155/2016/9513037

Vancouver

Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE et al. miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International. 2016;2016:9513037. doi: 10.1155/2016/9513037

Author

Due, Hanne ; Svendsen, Pernille ; Bødker, Julie Støve et al. / miR-155 as a Biomarker in B-Cell Malignancies. I: BioMed Research International. 2016 ; Bind 2016. s. 9513037.

Bibtex

@article{7d4762d29da5480ab069bee5b71443d9,
title = "miR-155 as a Biomarker in B-Cell Malignancies",
abstract = "MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during sample handling, and are important determinants of cellular processes controlling pathogenesis, progression, and response to treatment of several types of cancers including B-cell malignancies. miR-155 is an oncomiR with a crucial role in tumor initiation and development of several B-cell malignancies. The present review elucidates the potential of miR-155 as a diagnostic, prognostic, or predictive biomarker in B-cell malignancies using a systematic search strategy to identify relevant literature. miR-155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of miR-155 was further associated with poor prognosis. Elevated expression of miR-155 shows potential as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest miR-155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 studies prove that miR-155 has the potential to be a molecular tool in personalized medicine.",
keywords = "Journal Article, Review",
author = "Hanne Due and Pernille Svendsen and B{\o}dker, {Julie St{\o}ve} and Alexander Schmitz and Martin B{\o}gsted and Johnsen, {Hans Erik} and El-Galaly, {Tarec Christoffer} and Roug, {Anne Stidsholt} and Karen Dybk{\ae}r",
year = "2016",
doi = "10.1155/2016/9513037",
language = "English",
volume = "2016",
pages = "9513037",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - miR-155 as a Biomarker in B-Cell Malignancies

AU - Due, Hanne

AU - Svendsen, Pernille

AU - Bødker, Julie Støve

AU - Schmitz, Alexander

AU - Bøgsted, Martin

AU - Johnsen, Hans Erik

AU - El-Galaly, Tarec Christoffer

AU - Roug, Anne Stidsholt

AU - Dybkær, Karen

PY - 2016

Y1 - 2016

N2 - MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during sample handling, and are important determinants of cellular processes controlling pathogenesis, progression, and response to treatment of several types of cancers including B-cell malignancies. miR-155 is an oncomiR with a crucial role in tumor initiation and development of several B-cell malignancies. The present review elucidates the potential of miR-155 as a diagnostic, prognostic, or predictive biomarker in B-cell malignancies using a systematic search strategy to identify relevant literature. miR-155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of miR-155 was further associated with poor prognosis. Elevated expression of miR-155 shows potential as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest miR-155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 studies prove that miR-155 has the potential to be a molecular tool in personalized medicine.

AB - MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during sample handling, and are important determinants of cellular processes controlling pathogenesis, progression, and response to treatment of several types of cancers including B-cell malignancies. miR-155 is an oncomiR with a crucial role in tumor initiation and development of several B-cell malignancies. The present review elucidates the potential of miR-155 as a diagnostic, prognostic, or predictive biomarker in B-cell malignancies using a systematic search strategy to identify relevant literature. miR-155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of miR-155 was further associated with poor prognosis. Elevated expression of miR-155 shows potential as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest miR-155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 studies prove that miR-155 has the potential to be a molecular tool in personalized medicine.

KW - Journal Article

KW - Review

U2 - 10.1155/2016/9513037

DO - 10.1155/2016/9513037

M3 - Journal article

C2 - 27294145

VL - 2016

SP - 9513037

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

ER -